20:40 , May 18, 2018 |  BioCentury  |  Finance

CellCentric’s magic trio

Five years after pivoting from target discovery to drug development, epigenetics play CellCentric Ltd. is taking its sole asset CCS1477 into the clinic next month with $26 million from Morningside Venture Investments. The company believes...
02:28 , May 18, 2018 |  BC Week In Review  |  Financial News

CellCentric raises $26M to advance into the clinic

CellCentric Ltd. (Little Chesterford, U.K.) said it has raised $26 million in an undisclosed private financing round from existing investor Morningside Venture Investments. Early this summer, CellCentric plans to begin Phase I testing of lead candidate...
23:06 , May 14, 2018 |  BC Extra  |  Financial News

CellCentric raises $26M to advance into the clinic

CellCentric Ltd. (Little Chesterford, U.K.) said it has raised $26 million in an undisclosed private financing round from existing investor Morningside Venture Investments. Early this summer, CellCentric plans to begin Phase I testing of lead...
21:13 , Jan 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML) In vitro, cell culture and mouse studies identified a peptide-based inhibitor of the MYB-CREBBP interaction that could help treat AML. The inhibitor consisted of a retro-inverso form of a MYB fragment...
23:37 , Dec 21, 2017 |  BC Extra  |  Preclinical News

New pathway could overcome resistance to TKIs in cancer

In a paper published in Cancer Research, researchers at Dana-Farber Cancer Institute and colleagues discovered that the recently identified ufmylation pathway plays a role in resistance to tyrosine kinase inhibitors (TKIs), and suggested that promoting...
19:51 , Oct 26, 2017 |  BC Innovations  |  Translation in Brief

HATs off to epigenetics

Although the epigenetics field is heating up, most compounds on the market and in development are clustered around the same small set of targets. Now, a team led by AbbVie Inc. (NYSE:ABBV) has uncovered an...
18:17 , Sep 27, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML); prostate cancer In vitro, cell culture and mouse studies identified two dihydropyrazolopyridine-based dual CREBBP/EP300 inhibitors that could help treat AML and prostate cancer. Chemical synthesis and in vitro binding assays of...
23:09 , Aug 28, 2017 |  BC Week In Review  |  Clinical News

Genentech reports preclinical data for p300/CBP inhibitor in prostate cancer

Researchers at the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) reported preclinical data showing that prostate cancer candidate GNE-049 blocked expression of key proliferative genes and reduced tumor growth. In patient-derived xenograft mouse models of...
23:53 , Aug 23, 2017 |  BC Extra  |  Preclinical News

Genentech reports preclinical data for p300/CBP inhibitor in prostate cancer

Preclinical evidence supporting dual inhibition of E1A binding protein p300 (EP300; p300) and CREB binding protein (CREBBP; CBP) as an epigenetic strategy for treating prostate cancer is mounting. In a paper published in Cancer Research, researchers...
21:05 , Jul 18, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Esophageal cancer Cell culture and mouse studies suggest inhibiting Notch signaling in combination with dual EP300/CREBBP inhibitors could help treat esophageal adenocarcinoma. In two human esophageal adenocarcinoma cell lines, a dual EP300/CREBBP inhibitor tool compound...